Biomedicine Daily · Tuesday, 27 October 2026
CBA FRONTIER INSIGHTS
DeLLphi-305 Interim Analysis: Durvalumab Plus Tarlatamab First-Line Maintenance Cuts Death Risk 58% in Extensive-Stage Small Cell Lung Cancer
In the Phase III DeLLphi-305 trial, first-line maintenance durvalumab plus tarlatamab reduced the risk of death by 58% versus durvalumab alone in extensive-stage small cell lung cancer. Median OS was 21.1 months with the combination versus 12.7 months with monotherapy (OS HR 0.42; 95% CI 0.32-0.54; p<0.001). Median PFS was 7.4 versus 1.9 months (PFS HR 0.34; 95% CI 0.28-0.42; p<0.001).
Clinical readouts and safety
SAFFRON Global Phase III: Osimertinib Plus Savolitinib Cuts Risk of Progression or Death 45% in MET-Altered EGFR-Mutant Lung Cancer
The global Phase III SAFFRON trial showed that osimertinib combined with savolitinib reduced the risk of disease progression or death by 45% versus platinum doublet chemotherapy in MET-altered, EGFR-mutated NSCLC (PFS HR 0.55; 95% CI 0.42-0.72; p<0.001).
Phase III VOLGA: Perioperative Durvalumab Plus Neoadjuvant Enfortumab Vedotin Cuts Muscle-Invasive Bladder Cancer Recurrence Risk 49% and Death Risk 42%
Phase III VOLGA data show perioperative durvalumab plus neoadjuant enfortumab vedotin significantly improved EFS and OS in muscle-invasive bladder cancer. In a prespecified interim analysis of patients ineligible for or refusing cisplatin-based chemotherapy, the combination (n=233) versus control (n=229) showed an EFS HR of 0.51 (95% CI 0.38-0.67; p<0.0001) and an OS HR of 0.58 (95% CI 0.40-0.83; p=0.0027).
Phase III SANOVO Shows Osimertinib Plus Savolitinib Improves PFS and OS as First-Line Treatment in MET-Overexpressed EGFR-Mutated Advanced NSCLC
The Phase III SANOVO trial showed that first-line osimertinib plus savolitinib in advanced EGFR-mutated NSCLC with MET overexpression reduced the risk of progression or death by 44% versus osimertinib monotherapy in the ITT population, with improvements in both PFS and OS.
PD-1/VEGF Bispecific Ivonescimab Plus Chemotherapy Meets Overall Survival Primary Endpoint in Phase 3 HARMONi-GI1 Biliary Tract Cancer Trial
Phase 3 HARMONi-GI1 data presented at the 2026 ESMO Congress show that ivonescimab combined with chemotherapy met the overall survival primary endpoint as first-line treatment for advanced biliary tract cancer. The regimen was compared head-to-head against durvalumab plus chemotherapy.
Merck's sacituzumab tirumotecan global Phase III shows longer PFS and OS; FDA grants priority review
Merck reported the global Phase III TroFuse-005/ENGOT-en23/GOG-3095 trial of sacituzumab tirumotecan in endometrial cancer patients previously treated with platinum chemotherapy and anti-PD-(L)1 therapy, where both PFS and OS beat chemotherapy. The study enrolled 776 patients: PFS was 7.2 vs 3.9 months (HR=0.59, P<0.0001), OS was 19.0 vs 12.1 months (HR=0.68, P=0.0001), and ORR was 35.1% vs 17.3%. The US marketing application has been accepted by FDA with priority review.
Roche divarasib head-to-head in KRAS-mutant lung cancer: 338 patients, response rate 58.4%
Roche reported phase III head-to-head results for divarasib on October 25. The trial randomized 338 previously treated KRAS G12C lung cancer patients; median overall survival was 17.7 months versus 12.0 months, with a 44% reduction in risk of death. The source describes it as the first phase III head-to-head study of a next-generation KRAS G12C inhibitor against an approved first-generation inhibitor, and the headline gives a response rate of 58.4%.
Kelun-Biotech Reports OptiTROP-Lung06 Interim Analysis: sac-TMT Plus Pembrolizumab Beat Pembrolizumab Plus Chemo in PD-L1-Negative NSCLC
Kelun-Biotech presented an interim analysis of the Phase 3 OptiTROP-Lung06 trial at the 2026 ESMO congress. First-line sac-TMT plus pembrolizumab showed significantly superior PFS versus pembrolizumab plus chemotherapy in driver-gene-negative, PD-L1-negative NSCLC, at 15.0 months versus 5.7 months.
Phase III OptiTROP-Lung04 Final Analysis Shows sac-TMT Monotherapy Reached Median OS of 25.9 Months in EGFR-Mutated NSCLC After EGFR-TKI Progression
In the final analysis of the phase III OptiTROP-Lung04 study, sacituzumab tirumotecan (sac-TMT) monotherapy achieved a median overall survival of 25.9 months in patients with EGFR-mutated NSCLC that progressed after EGFR-TKI treatment, compared with 17.4 months in the platinum-based chemotherapy group.
2026 ESMO Abstracts Focus on Next Treatment After CDK4/6 Inhibitor Progression in Advanced Breast Cancer
Three 2026 ESMO abstracts address subsequent therapy for HR+/HER2− advanced breast cancer after progression on CDK4/6 inhibitors, covering atirmociclib, abemaciclib, and giredestrant combination regimens respectively.
2026 ESMO: ECLYPse, TRIDENTE and BRICKET Test Post-Targeted-Therapy Strategies in BRAF V600E-Mutant mCRC, ctDNA-Guided Retreatment Shows No Objective Responses
At ESMO 2026, three phase II studies of post-targeted-therapy strategies in BRAF V600E-mutant metastatic colorectal cancer (mCRC) were presented: ECLYPse met its primary endpoint, TRIDENTE showed clinical activity, and BRICKET observed no objective responses.
Regulatory and policy
FDA approves talazoparib with enzalutamide for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer with HRR gene mutations
On October 26, 2026, the FDA approved talazoparib plus enzalutamide for adults with metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer harboring HRR gene mutations.
NMPA Grants World-First Approval to Bayer's Asundexian to Reduce Ischemic Stroke or High-Risk TIA Risk
The NMPA has granted the world's first approval of Bayer's asundexian to reduce stroke risk in adults with ischemic stroke or high-risk transient ischemic attack (TIA), excluding cardioembolic stroke. The drug received priority review, with approval taking about half a year from acceptance.
Xinjiang Completes DRG/DIP Half-Year Settlement Across 14 Regions, Paying 166.23 Hundred Million Yuan
Xinjiang's medical insurance bureau has completed a DRG/DIP half-year settlement covering 14 pooling regions and 2758 medical institutions, with cumulative payments of 166.23 hundred million yuan. From January to June 2026, 8065.25 ten-thousand person-times of insurance benefits were paid across the region, with fund spending of 243.86 hundred million yuan. The settlement used case quality control, cost review, result verification and a closed-loop process of online double-blind review plus tiered review, reviewing more than 4.4 ten-thousand cases and paying 7.66 hundred million yuan.
STAT+: NIH’s new vaccine injury center has broad goals beyond RFK Jr.’s focus on shots
A new NIH vaccine injury center will bring post-infection long-term symptoms into its research scope, covering groups such as long Covid patients. Earlier this month, Robert F. Kennedy Jr. and other federal health officials announced the center would focus on patients with vaccine injuries; days later, two NIH leaders said its goals also include long-term symptoms after infection. One senior NIH official, speaking anonymously, said it is hard to distinguish whether long Covid symptoms stem from a vaccine or an infection because many patients have experienced both, and the immunological response mechanism and treatment are similar.
Fenebrutinib gets priority review by the FDA
Roche's NDA for fenebrutinib was accepted by the FDA with priority review on 2026-09-30. The drug is not yet approved and no PDUFA date has been disclosed.
STAT+: House lawmaker probes PBMs for ‘punitive’ audits of independent pharmacies
James Comer, chairman of the U.S. House Committee on Oversight and Government Reform, is investigating whether CVS Caremark, OptumRx and Express Scripts retaliated against independent pharmacies with audits for supporting legislation.
Statement on improving adverse event reporting of compounded drugs to protect patients
The FDA announced it is strengthening oversight of adverse event reporting for compounded drugs, requiring outsourcing facilities to meet their reporting obligations and taking appropriate enforcement action against non-compliant facilities. During a 2018 inspection of BioTE Medical, the FDA found 4,202 adverse events that had never been reported, involving compounded hormone pellets occurring between 2013 and 2018; because key information was missing, the FDA could attribute only 61 of them to pellets containing testosterone.
Ivonescimab Plus Chemotherapy for First-Line Biliary Tract Cancer Proposed for CDE Priority Review
A new indication for ivonescimab, filed by Akeso/Summit (Kangfang Sainuo), combining ivonescimab with chemotherapy as first-line treatment for locally advanced or metastatic biliary tract cancer, has been proposed for priority review by the CDE. The information appeared on the CDE website on October 23, 2026. Biliary tract cancer is usually diagnosed late with poor prognosis; patients with advanced disease have a survival rate of only 2-3%.
The Center for Drug Evaluation and Research's ARC Program Releases 2026 Annual Report
FDA CDER's Accelerating Rare disease Cures (ARC) Program has released its 2026 Annual Report, summarizing annual progress under three goals: scientific and regulatory innovations, engagement and education, and operations. The report presents the ARC 2025–2030 Strategic Plan, along with the LEADER 3D case studies and expanded educational resources, advances in statistical methods, translational science research, and international regulatory collaboration. According to the report, half of CDER's novel drug approvals in 2025 represented rare disease treatments.
bsky.appSignal or noise? > Opus Genetics Eyes 2029 Runway as Presbyopia Drop Wins FDA Approval - TradingView >> Comment below! #strategy #competitiveintelligence #marketing #competitivemarketing #pharmaceutical #healthcare #biotech #pharma
Opus Genetics' presbyopia program has won FDA approval. The post merely relays a TradingView headline, mentions a 2029 commercialization outlook, and provides no product name or specific approval details.
Industry and deals
China Innovation Drug BD Potential Deal Value Nears $100 Billion in First Half, Pharma Majors Press On
Potential deal value of out-licensing (BD) transactions for China's innovative drugs approached $100 billion in the first half as multinational pharma continued pursuing deals. Since September, Gilead Sciences reached a definitive agreement with PepStar Therapeutics to acquire its oral IL-23R inhibitor program, whose lead candidate is HCXT-2001, for a $1.275 billion cash upfront payment. In late September, Ciprapirin (SPR2015 developer) and Merck signed a global exclusive license for preclinical oral KRAS G12D (ON) inhibitor SPR2015, with $400 million upfront and total potential value up to $2.13 billion; the deal has taken effect.
STAT+: Nonprofit Bon Secours Mercy Health strikes $5.7 billion deal for surgery center chain
Bon Secours Mercy Health announced plans to acquire Surgery Partners in a deal valued at $5.7 billion, expected to close in the first quarter of 2027. Surgery Partners operates more than 200 ambulatory surgery centers, short-stay hospitals, and multispecialty physician practices across 30 states. The deal would also deepen Bon Secours Mercy Health's ties with Bain Capital.
Gilead Acquires PepStar's Oral IL-23R Program for $1.275 Billion Upfront
Gilead will acquire the oral IL-23R inhibitor program of PepStar Therapeutics for an upfront cash payment of $1.275 billion, gaining global rights including lead candidate HCXT-2001. HCXT-2001 is in clinical development as an oral macrocyclic peptide IL-23R inhibitor with a long half-life, offering a potential differentiated therapy for IBD and possible expansion into psoriasis. Closing remains subject to customary conditions and is expected in the fourth quarter of 2026. Eight Roads was PepStar's angel investor and added investments across three consecutive rounds.
MetaTen Pharma and Eli Lilly Strike AI Drug Delivery Deal Worth Up to 1.1 Billion Dollars
MetaTen Pharma (7666.HK) announced a strategic collaboration with Eli Lilly carrying an upfront payment of over ten million US dollars and a total value of up to 1.1 billion US dollars, focused on AI-driven drug delivery solutions. The partners will jointly develop novel lipid nanoparticle (LNP) delivery systems and explore tissue-specific delivery technology adaptable to multiple therapeutic modalities, with Lilly mobilizing resources across drug discovery, clinical development and commercialization.
US biotechs take lion’s share of $54.5B VC money raised since 2025
From early 2025 through the third quarter of 2026, global biopharma financing reached $54.5B, of which U.S. companies raised $37.2B, about 68%. The San Francisco Bay Area and Boston raised $12.8B and $10.2B respectively, together about 62% of U.S. funding, while European biopharma companies raised $9.2B. Half of the $1.1B raised in the most recent quarter came from 5 of 32 rounds, and J.P. Morgan projects full-year 2026 financing of about $33B.
Corxel, an obesity drugmaker, to go public via SPAC deal
Corxel plans to go public through a merger with the U.S. SPAC Amanat Acquisition Corp., along with a $300 million private financing to advance late-stage development of CX11. The deal centers on CX11, an oral GLP-1 drug in-licensed from Vincentage Pharma, and a preclinical obesity candidate targeting amylin. JX10, an acute ischemic stroke drug obtained from Biogen, is excluded and will remain with the private parent company.
Biotech IPOs raise $7.5B as sector’s performance rally flattens
Biotech IPOs raised $7.5 billion across 22 offerings in the first three quarters of 2026, according to J.P. Morgan. The XBI fell less than 1% in the third quarter as the sector's rally flattened. Parabilis Medicines' summer debut raised $670 million, the largest IPO raise in biotech history, and at least 31 biotechs had gone public as of Oct. 26.
Research papers
Scientists made a 'low-oxygen hypoxia pill': two drugs that make blood release less oxygen into tissues. Given daily to mice that already had Parkinson's-like movement problems, it improved their movement within 1-2 weeks. It also more than doubled lifespan in mice with a rare energy disorder.
A PNAS study shows that an oral hypoxia combination of GBT601 and PT2399 improves Parkinson's-like motor deficits and extends lifespan in Leigh syndrome mice. In the Ndufs4-knockout Leigh syndrome model, median lifespan increased from 62 days to 158 days. The combination also reversed motor phenotypes in an alpha-synuclein toxicity model of Parkinson's disease and halted progression of motor problems in a Friedreich ataxia model. DOI: 10.1073/pnas.2618654123.
Microsoft MAI-DxO Hits 85.5% Accuracy on Complex Cases, With Tests Costing Nearly 40,000 Yuan
Microsoft published new results for MAI-DxO in Science, reporting 85.5% diagnostic accuracy on complex cases, versus 20% for unaided human physicians. First released in 2025, the tool was described in reports as Microsoft's best-performing AI diagnostic system to date, with a testing cost approaching 40,000 yuan.
doi.orgColorectal cancers with distinct metastatic potential trigger divergent early T cell responses
Colorectal cancers with different metastatic potential induce distinct early T cell responses: nonmetastatic tumors trigger cytotoxic and Th1-like programs, while pro-metastatic tumors leave T cells in a naïve-like, hypoactivated state. Using orthotopic organoid transplantation and T cell fate mapping, the study found that pro-metastatic tumors downregulate MHCII, and targeting Ciita reduced CD4+ clonal expansion in nonmetastatic organoids and promoted tumor progression.
How the TREX-2 complex associates with the nuclear pore
Agnieszka Obarska-Kosinska and colleagues built an extended model of the human nuclear pore, adding five nucleoporins and resolving how the nuclear basket and the TREX-2 complex attach to the nuclear ring. Combining cryo-electron tomography, AI-assisted modeling and crosslinking mass spectrometry, the work reveals the spatial organization of the pore relevant to mRNP export.
Amyloid-mediated RNA uptake by sperm for embryonic delivery
Amyloid fibrils in seminal plasma can bind RNA, enter sperm, and deliver their RNA cargo to the zygote at fertilization. After entry into the zygote, molecular chaperones release the RNA cargo for translation, explaining how extracellular RNA in semen influences early embryonic development.
The 9-1-1 complex protects ssDNA gaps in BRCA2-deficient cancer
Research shows that the 9-1-1 complex protects BRCA2-deficient cancer cells from lethal ssDNA gap accumulation by suppressing PRIMPOL-dependent gap formation and promoting POLζ-mediated filling. The mechanism also restrains EXO1 degradation and reveals an ATR-independent role in post-replicative repair; the study establishes gap length as a key determinant of repair pathway choice.
Spatial niche organization shapes clinical heterogeneity in Ewing sarcoma
Single-cell and spatial resolution analysis of 135 Ewing sarcoma patients showed that spatial niche composition stratifies patients into four types with distinct overall survival patterns. Analysis of more than 3 million cells identified five recurrent tumor cell transcriptional states, twelve stromal and immune cell types, and eight niches. The four-type classification was validated in bulk transcriptomic data from two independent cohorts.
Early Prenatal Cell-Free DNA Methylation Landscape Informs Epigenetic Purification of the Circulating Fetal Genome
A first-trimester fetal cfDNA methylation reference map guided epigenetic enrichment by epiSIFT, raising the median fetal cfDNA fraction from 5.1% to 28.4% across 28 prenatal plasma samples.
Targeting IGF2BP1 Creates a Mitotic Vulnerability in Colorectal Carcinoma
A bioRxiv preprint shows that targeting IGF2BP1 disrupts mitosis in colorectal cancer, with BTYNB and paclitaxel showing synergistic effects in cell models. IGF2BP1 is highly expressed in CRC, rises with tumor stage, and correlates with poorer survival; its genetic depletion or pharmacological inhibition reduces cell viability and induces mitotic abnormalities and apoptosis.
Aquaporin-4 Regulates Edema, Sustains Astrocyte Differentiation, and Constrains Immunosuppressive Remodeling in Glioblastoma
An RCAS/tv-a mouse study shows that Aqp4 loss worsens glioblastoma edema, shortens survival, and remodels astrocyte states. In human glioblastoma samples, AQP4 expression is upregulated and correlates with peritumoral edema.
Affinity Maturation Enables Dual Targeting of Cancer-Associated MUC1-Tn/STn and Drives Potent Tumor Control
The anti-MUC1-Tn antibody 5E5 was affinity-matured through structure-guided directed evolution and yeast surface display, yielding variants that recognize both MUC1-Tn and MUC1-STn with high affinity. Co-crystal structures show that HCDR3 residue 98 tunes glycoform preference: Tyr98 favors MUC1-Tn, while His98 strengthens MUC1-STn binding, and both support high-affinity recognition of the two glycoforms.
Longitudinal AI Models Predict Cancer Adverse Events
SPARC, a transformer-based model, uses routine longitudinal health data to predict cancer-related adverse event risk and achieved state-of-the-art performance on development, prospective, and external multi-center cohorts. It was pre-trained and fine-tuned on 101,920,379 measurements from 224,047 patients with cancer, with a prospective validation cohort of 23,126 patients, public external datasets of 26,012 patients, and external multi-hospital cohorts reporting 562,620 and 206,840 patients.
Pregnancy Outcomes After Living Kidney Donation.
A Canadian matched cohort study of 385 pregnancies among 252 living kidney donors found that pregnancy after donation was associated with a higher risk of a composite endpoint of hospitalization for gestational hypertension, preeclampsia, or eclampsia. The composite endpoint occurred in 11.9% of donor pregnancies versus 8.3% in matched nondonor pregnancies (RR 1.51, 95% CI 1.10-2.08). Small for gestational age at birth occurred in 13.8% versus 7.9% (RR 1.86, 95% CI 1.37-2.52); most postdonation pregnancies were uncomplicated.
arxiv.orgPrincipia: Test-Time Hypotheses to Principle Construction for Scientific Discovery
Principia is an LLM-based framework that constructs comparative causal hypotheses at test time from related inputs and observed outcomes, then distills recurring relationships into scientific principles that are continually revised as new observations arrive. It outperforms baselines relying on internal knowledge, external sources, or experience summaries across benchmarks in molecular optimization, protein engineering, gene perturbation, and molecular property prediction, and its generated principles are plausible and consistent with the scientific literature. Code: https://github.com/DongkiKim95/Principia
Genetic control and tissue specificity of transcriptomic rhythmicity
The team analyzed 50 tissues from GTEx v10 and detected rhythmically expressed genes in 49 of them, identifying 167 cd-eQTLs involving 51 genes across 28 tissues. Most cd-eQTLs altered oscillation amplitude, while others affected acrophase or both; effects on core circadian genes were consistent across tissues, whereas effects on clock-regulated genes were largely tissue-specific.
Methods and resources
Recordanelles capture transient gene expression in single human cells.
Recordanelles, synthetic organelles, can record RNA persisting for several days within single human cells and be read out with single-cell sensitivity. The technology addresses the problem that RNA sequencing cannot capture transient transcriptional changes at a transcriptome-wide scale over long periods. It summarizes research by Reinkemeier et al. published in Nature Biotechnology (DOI: https://doi.org/10.1038/s41587-026-03327-6).
Multiplexed and implantable fiber sensor for real-time blood monitoring.
A research team developed MIFS, a multiplexed implantable fiber sensor that monitors Na+ and K+ ions in the bloodstream in real time. MIFS integrates three parallel liquid metal channels with a multilayer surface-electrode architecture to enhance sensitivity, reduce sensing drift, maintain mechanical flexibility, and provide the biocompatibility required for vascular implantation. In vivo testing in rabbit models and validation in human blood samples showed real-time, stable sensing consistent with conventional ex vivo measurements. The paper's DOI is 10.1126/sciadv.aei9767.
fastGxE is a powerful method for uncovering genotype–environment interactions in biobanks
fastGxE is a scalable method for analyzing genotype-environment interactions that accelerates genome-wide scans in biobank data. Applied to the UK Biobank, it identified previously uncharacterized interaction loci for physical traits and routinely assayed blood biomarkers, revealing context-dependent genetic effects.
HDOCK-Multimer Combines Docking and Combinatorial Assembly to Improve Large Protein Complex Structure Prediction
Shengyou Huang's team at Huazhong University of Science and Technology has proposed HDOCK-Multimer (HDM), which integrates molecular docking, combinatorial assembly and a genetic algorithm to improve structural prediction of large multichain protein complexes. Published in Nature Computational Science, the study shows HDM outperformed CombFold, MoLPC and AlphaFold-series methods overall across three benchmark sets: 35 large heteromeric complexes, 172 large protein complexes and 7 CASP15 targets.
Quantification method affects replicability of eQTL analysis, colocalization and TWAS
A methods study of eQTL analysis shows that transcript annotation and quantification methods used in upstream RNA-seq processing can affect eQTL mapping, TWAS, and colocalization with GWAS.
youtube.comDiversifying (Positive) Selection — Harmit Malik
In an iBiology Techniques expert lecture, Harmit Malik explains how sequence analysis identifies genes under diversifying (positive) selection. The core is comparing the nonsynonymous substitution rate with the synonymous substitution rate of protein-coding genes; an elevated nonsynonymous rate at host-virus conflict interfaces suggests potentially beneficial mutations favored by natural selection. Diversifying (positive) selection, also called adaptive evolution, differs from purifying selection: it increases amino acid diversity in protein-coding genes and raises the fixation rate of potentially beneficial variants in populations.
arxiv.orgControlled Evaluation of EEG Foundation Models: Random Initialisation, Band-Power and Validation-Selected Probes
A controlled evaluation of five publicly released EEG foundation models, with probe layers selected on validation sets, shows random initialisation matches or exceeds pretraining for half of them on sleep and emotion tasks. The evaluation covers five benchmarks, four added task families and multiple seeds, and includes five public models plus an in-house JEPA-style model. No model beats a five-band log-power baseline on emotion or motor imagery.
Opinion and commentary
youtube.comGlobal Consensus Renames Polycystic Ovary Syndrome as Polyendocrine Metabolic Ovarian Syndrome
In a Lancet program, experts described a renaming of polycystic ovary syndrome (PCOS) that won 98% consensus support. The new name is polyendocrine metabolic ovarian syndrome (PMOS), and the old and new names will run in parallel for 3 years. The condition affects about 170 million women of reproductive age worldwide and many postmenopausal women; the rename aims to highlight its endocrine, metabolic, reproductive, psychological, and skin manifestations. Ultrasound assessment of 2000 women showed PCOS patients do not have more benign or pathological ovarian cysts, but more antral follicles.
youtube.comResearch integrity in the age of AI
Editors at The Lancet describe their processes for safeguarding research integrity at submission, external review, acceptance, and after publication, and introduce a research integrity committee being established. The submission system automatically screens for duplicate submission, plagiarism, and unverified references; before review, editors check protocols, statistical analysis plans, ethics approval numbers, and data verification by at least 2 authors; line-by-line checks after external review and acceptance cover numbers, references, tables, and figures.
Nanotherapy targets senescent cells
A study by Hinterleitner et al., published in Science in 2026, shows that senescent-cell-targeted nanotherapy can ameliorate fibrosis in cancer and overcome immune exclusion, DOI 10.1126/science.aeg4791. Cellular senescence can support tissue repair and suppress carcinogenesis, but persistence of senescent cells drives chronic inflammation, fibrosis and immune dysfunction. Drugs targeting senescent cells have shown promise in preclinical models, but toxicity has limited translation.
In brief
- Clinical and prognostic significance of the C-reactive protein-albumin-lymphocyte (CALLY) index in breast cancer: a systematic review and meta-analysismedrxiv.org
- Author Correction: Sex-specific biological aging clocks across organs and omicsnature.com
- Cross-Tissue Concordance of Blood-Trained Protein EpiScores in Donor-Matched GTEx Tissuesbiorxiv.org
- Young adults with cancer report putting off appointments, getting dismissed by doctorsmedicalxpress.com